CVS Health's Zero-Cost Coverage Paves Way For OTC Birth Control Access
Portfolio Pulse from Vandana Singh
CVS Health Corp announced its drug plans will cover the first over-the-counter birth control pill, Opill by Perrigo Company Plc, at no charge for many health plan sponsors, marking a significant step in reproductive healthcare accessibility. This follows CVS and Walgreens Boots Alliance Inc's decision to dispense the abortion pill mifepristone, aligning with FDA guidelines. The coverage by CVS Caremark aims to widen contraception access, especially for younger women and those in rural areas. Opill, approved by the FDA in July 2023 for all ages, is priced at $19.99 for a one-month supply.
April 05, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CVS Health's decision to cover Opill at no charge could enhance its reputation and potentially increase customer loyalty and market share.
By covering the cost of Opill, CVS positions itself as a leader in reproductive healthcare access, which could attract customers valuing healthcare innovation and corporate responsibility. This move may also increase foot traffic and sales, positively impacting CVS's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Perrigo's Opill being covered by CVS Caremark could lead to increased sales and visibility for the product.
The inclusion of Opill in CVS Caremark's preventive services list not only enhances the product's visibility but also makes it more accessible, likely leading to increased sales. This positive development could have a favorable impact on Perrigo's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Walgreens Boots Alliance's decision to dispense the abortion pill mifepristone, similar to CVS, reflects its commitment to reproductive healthcare, potentially affecting its market position.
Walgreens' decision to dispense mifepristone, following FDA guidelines, positions it alongside CVS as a proactive player in reproductive healthcare. This could enhance its reputation and potentially impact its stock positively in the short term, as it may attract customers who value access to comprehensive healthcare services.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 70